^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CD69 overexpression

    i
    Other names: CD69 Molecule, CLEC2C, CD69 Antigen (P60, Early T-Cell Activation Antigen), Early T-Cell Activation Antigen P60, Leukocyte Surface Antigen Leu-23, Early Activation Antigen CD69, BL-AC/P26, GP32/28, MLR-3, AIM, EA1, C-Type Lectin Domain Family 2, Member C, Activation Inducer Molecule (AIM/CD69), C-Type Lectin Domain Family 2 Member C, Early Lymphocyte Activation Antigen, Activation Inducer Molecule, CD69 Antigen, CD69
    Entrez ID:
    969
    11ms
    CD169 Expression in Lymph Nodes is Associated with Increased Infiltration of CD8 T Cells in Tumors: A Systematic Review and Meta-Analysis. (PubMed, J Immunol Res)
    However, the number and heterogeneity of the studies should be taken into consideration when evaluating the analysis. High-quality randomized controlled trials on the association between CD169 and CD8 expression are needed to verify these effects.
    Retrospective data • Review • Journal
    |
    CD8 (cluster of differentiation 8) • SIGLEC1 (Sialic Acid Binding Ig Like Lectin 1)
    |
    CD8 expression • CD69 overexpression • CD8-H
    over1year
    A high risk of progression from smoldering to symptomatic multiple myeloma was predicted by bone marrow and circulating gamma delta T cells. (IMW 2023)
    BM γδ T cells acquire a dysfunctional phenotype during MM progression, which significantly impacts patient prognosis. Accordingly, circulating γδ T cells, which mimic the BM milieu, may serve as a potentially less invasive means for follow-up and prognostication of patients affected by monoclonal gammopathies.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • CD69 (CD69 Molecule) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • CXCR3 (C-X-C Motif Chemokine Receptor 3)
    |
    PD-1 expression • CD69 overexpression • HAVCR2 expression • IFNG expression
    over1year
    Single-cell transcriptomics reveals multiple chemoresistant properties in leukemic stem and progenitor cells in pediatric AML. (PubMed, Genome Biol)
    Our analysis reveals leukemia stem cell and OXPHOS as two major chemoresistant features in human AML patients. CD69 may serve as a potential biomarker in defining a subpopulation of chemoresistant leukemia stem cells. These findings have important implications for targeting residual chemo-surviving AML cells.
    Journal
    |
    CD69 (CD69 Molecule)
    |
    CD69 overexpression
    over2years
    Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib. (PubMed, Exp Cell Res)
    Herein, we found that the erythroid differentiation inducers activin A and aclacinomycin A induced expression of erythroid markers (α-globin, ζ-globin, GATA-1, and glycophorin A) and simultaneously reduced CD69 levels in K562 CML cells. These results suggest that CD69 inhibits activin A induction of erythroid differentiation-mediated CML cell sensitivity to imatinib via MT2A. Therefore, activin A induction of erythroid differentiation sensitizes BCR-ABL-positive cells to imatinib by downregulating the erythroid differentiation suppressors CD69 and MT2A.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD34 (CD34 molecule) • CD69 (CD69 Molecule) • GATA1 (GATA Binding Protein 1)
    |
    CD69 overexpression
    |
    imatinib • aclarubicin